Ireland· IE-PA-EU/1/19/1408/001
Tavlesse
A fostamatinib product containing fostamatinib, registered in Ireland by Rigel Pharmaceuticals B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Fostamatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC B02BX09 (fostamatinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Fostamatinib · ATC B02BX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- FOSTAMATINIB
- Manufacturer
- Rigel Pharmaceuticals B.V.
- Country
- Ireland (IE)
- ATC code
- B02BX09
- ATC class
- Fostamatinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- July 20, 2026
Packs & prices · 1
- ie_pa_numberEU/1/19/1408/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
545 interactions on record for fostamatinib.
Graded by severity as the source publishes them — 50 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fostamatinib · interactions on record
545 records
- 50 severe
- 493 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fostamatinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayTavlesseGrifols
- CanadaTAVALISSEMEDISON PHARMA CANADA INC.
- CzechiaTAVLESSEInstituto Grifols, S.A., Barcelona
- SpainTAVLESSE 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAInstituto Grifols S.A.
- FinlandTavlesseInstituto Grifols S.A.
- FranceTAVLESSE 100 mg, comprimé pelliculéINSTITUTO GRIFOLS
- United KingdomTavlesse 100mg tabletsGrifols UK Ltd
- IcelandTAVLESSEInstituto Grifols S.A.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tavlesse
- Liechtenstein · Tavlesse
- Norway · Tavlesse
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3eda34e8-1e7a-4903-98a7-0edb3235770b GET /v1/drugs/3eda34e8-1e7a-4903-98a7-0edb3235770b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"B02BX09"
],
"strength": null,
"pa_number": "EU/1/19/1408/001",
"substances": [
"FOSTAMATINIB"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "09/01/2020",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about fostamatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.